Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from BioNTech SE ( (BNTX) ) is now available.
On May 22, 2026, BioNTech announced it will present new clinical data and trial updates from its late-stage oncology pipeline at the 2026 ASCO Annual Meeting in Chicago, running from May 29 to June 2. The centerpiece will be oral presentations on pumitamig and gotistobart, alongside four “trial in progress” posters that highlight the breadth of its pivotal and combination studies, including several antibody-drug conjugate programs.
Interim Phase 2 data from the ROSETTA Lung-02 study in first-line non-small cell lung cancer have shown encouraging anti-tumor activity for pumitamig plus chemotherapy, reinforcing earlier signals in small cell lung cancer and triple-negative breast cancer and informing the ongoing Phase 3 comparison versus pembrolizumab plus chemotherapy. Separately, Phase 2 data from PRESERVE-004 in heavily pre-treated platinum-resistant ovarian cancer demonstrated durable responses and meaningful overall survival with gotistobart plus pembrolizumab, supporting its potential as a chemotherapy-free option and underscoring BioNTech’s push to establish a competitive late-stage oncology franchise.
The ASCO line-up also showcases BioNTech’s expanding ADC portfolio, with trials of HER3-targeted BNT326/YL202, B7H3-targeted BNT324/DB-1311 in metastatic castration-resistant prostate cancer, and HER2-targeted trastuzumab pamirtecan in recurrent endometrial cancer. Collectively, the more than 25 ongoing Phase 2 and Phase 3 trials, including 13 pivotal studies, signal a strategic acceleration toward a first wave of oncology products that could diversify the company’s revenue base beyond vaccines and strengthen its position in competitive solid tumor markets.
The most recent analyst rating on (BNTX) stock is a Buy with a $158.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
The score reflects a strong financial backstop (very low leverage and substantial liquidity, with improved recent free cash flow) but a weak near-term earnings profile (losses and volatile revenues). Technical indicators are bearish with the stock below key moving averages and negative MACD. The latest earnings call supports the medium-term pipeline narrative, but 2026 guidance points to lower revenues and higher spend, keeping the overall score in the mid-range.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a global next-generation biopharmaceutical company focused on developing novel therapies for cancer and other serious diseases. In oncology, it is building a diversified late-stage pipeline across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, often in collaboration with partners such as Bristol Myers Squibb, OncoC4, Duality Biologics, Genentech, Genmab, MediLink and Pfizer.
Average Trading Volume: 1,150,774
Technical Sentiment Signal: Sell
Current Market Cap: $22.85B
See more insights into BNTX stock on TipRanks’ Stock Analysis page.